Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
Christoph StraubeStephanie E CombsDenise BernhardtJens GemptBernhard MeyerClaus ZimmerFriederike Schmidt-GrafPeter VajkoczyArne GrünFelix EhretDaniel ZipsDavid KaulPublished in: Journal of neuro-oncology (2024)
Factors such as MGMT promoter methylation status and treatment interval play crucial roles in determining patient outcomes after second surgery. Personalized treatment strategies should consider these factors to optimize the management of rGBM. Prospective research is needed to define the value of re-RT after second surgery and to inform decision making in this situation.
Keyphrases
- minimally invasive
- coronary artery bypass
- dna methylation
- surgical site infection
- early stage
- gene expression
- transcription factor
- lymph node
- case report
- genome wide
- randomized controlled trial
- radiation induced
- clinical trial
- percutaneous coronary intervention
- coronary artery disease
- combination therapy
- prognostic factors
- replacement therapy
- phase iii
- data analysis